2022 – Bibliose

Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.

16 juin 2022

admin_bibliose

Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies.

Dr Anne-Catherine POULEUR : Cardiologue - institut cardiovasculaire Saint Luc - Bruxelles BELGIQUE

2022, REPLAY

Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination.

19 mai 2022

admin_bibliose

Dr Silvia OGHINA : Cardiologue APHP Henri Mondor - Créteil

Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination. https://pubmed.ncbi.nlm.nih.gov/34888361/

2022, REPLAY

Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis.

19 mai 2022

admin_bibliose

Dr Vincent ALGALARRONDO : Cardiologue APHP Bichat - Paris

Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis.

https://pubmed.ncbi.nlm.nih.gov/35439584/

2022, REPLAY

ST‑elevation myocardial infarction among cardiac amyloidosis patients; a national readmission database study

24 mars 2022

admin_bibliose

Pr François ROUBILLE : Cardiologue resp. équipe médicale insuffisance cardiaque - CHU de Montpellier

ST‑elevation myocardial infarction among cardiac amyloidosis patients; a national readmission database study. https://pubmed.ncbi.nlm.nih.gov/35048207/

PMID : 35048207

2022, REPLAY

Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis

24 mars 2022

admin_bibliose

Dr Damien EYHARTS : Cardiologue CHU de Toulouse

Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis https://pubmed.ncbi.nlm.nih.gov/35178887/

PMID : 35178887

2022, REPLAY

Utilization and tolerance of beta-blockers among patients with AL amyloidosis.

24 février 2022

admin_bibliose

Jean-Jacques VON HUNOLSTEIN : Cardiologue Hopital Civil STRASBOURG

Utilization and tolerance of beta-blockers among patients with AL amyloidosis.

https://pubmed.ncbi.nlm.nih.gov/34549676/

PMID : 34549676

2022, REPLAY

Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatmen

24 février 2022

admin_bibliose

Antoine JOBBE-DUVAL : Cardiologue HCL LYON

Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment.

https://pubmed.ncbi.nlm.nih.gov/34768388/

PMID : 34768388

2022, REPLAY

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.

10 février 2022

admin_bibliose

Patricia RÉANT : Cardiologue - CHU de BORDEAUX

Long-Term Survival With Tafamidis in Patients
With Transthyretin Amyloid Cardiomyopathy.

https://pubmed.ncbi.nlm.nih.gov/34923848/

PMID : 34923848

2022, REPLAY

Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.

10 février 2022

admin_bibliose

Emmanuelle BERTHELOT : adjointe chef de service, Cardiologue - APHP CHU Bicêtre

Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis.

https://pubmed.ncbi.nlm.nih.gov/32729170/

PMID : 32729170

2022, REPLAY

Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis

27 janvier 2022

admin_bibliose

Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis

Jean-Pierre GUEFFET : Cardiologue Hôpital Privé du Confluent - Nantes

https://pubmed.ncbi.nlm.nih.gov/34734/

2022, REPLAY